bioAffinity Technologies received written notice from Nasdaq confirming it has regained compliance with the Minimum Bid Price Rule and Rights/Warrants Rule, allowing its common stock and warrants to continue trading on the Nasdaq Capital Market. Consequently, a scheduled hearing before the Nasdaq Hearings Panel was cancelled. The company had previously been notified of non-compliance due to a bid price below $1.00 per share for thirty consecutive days but was ineligible for a standard compliance period because it executed a reverse stock split within the prior year. As of September 8, 2026, there were 1,166,625 outstanding shares with an aggregate market value of approximately $10.4 million. bioAffinity Technologies operates in the biotechnology industry, developing noninvasive healthcare solutions for the early detection and monitoring of lung disease.
